Observational study of the efficacy of prolonged-release metformin in people with prediabetes

References

• American Diabetes Association. 2 Classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care. 2019;42 (Suppl 1):S13–S28.
   PubMed Web of Science ®Google Scholar
• Rydén L, Grant PJ, Anker SD, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on Diabetes, Pre-diabetes, and Cardiovascular diseases Of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34(39):3035–3087.
   PubMed Web of Science ®Google Scholar
• Xu T, Liu W, Cai X, et al. Risk of coronary heart disease in different criterion of impaired fasting glucose: a meta-analysis. Medicine (Baltimore). 2015;94(40):e1740.
   PubMed Web of Science ®Google Scholar
• Huang Y, Cai X, Mai W, et al. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ. 2016;355:i5953
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 3 Prevention or delay of type 2 diabetes: standards of medical care in diabetes-2019. Diabetes Care. 2019;42 (Suppl 1):S29–S33.
   PubMedGoogle Scholar
• Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.
   PubMed Web of Science ®Google Scholar
• Hostalek U, Gwilt M, Hildemann S. Therapeutic use of metformin in prediabetes and diabetes prevention. Drugs. 2015;75(10):1071–1094.
   PubMed Web of Science ®Google Scholar
• Boyko EJ. Observational research–opportunities and limitations. J Diabetes Complications. 2013;27(6):642–648.
   PubMed Web of Science ®Google Scholar
• Glucophage® SR [Internet]. European summary of product characteristics. [cited May 2019]. Available at https://www.medicines.org.uk/emc/product/6298
   Google Scholar
• Aroda VR, Knowler WC, Crandall JP, et al. Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. Diabetologia. 2017;60(9):1601–1611.
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care. 2003;26:977–980.
   PubMed Web of Science ®Google Scholar
• Delahanty LM. Weight loss in the prevention and treatment of diabetes. Prev Med. 2017;104:120–123.
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care. 2015;38:51–58.
   PubMed Web of Science ®Google Scholar
• Ramachandran A, Arun N, Shetty AS, et al. Efficacy of primary prevention interventions when fasting and post-glucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP-1 and IDPP-2). Diabetes Care. 2010;33(10):2164–2168.
   PubMed Web of Science ®Google Scholar
• Holman RR, Blackwell L, Stratton IM, et al. Six-year results from the Early Diabetes Intervention Trial. Diabet Med. 2003;20(Suppl 2):S15.
   Google Scholar
• Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015;3:866–875.
   PubMed Web of Science ®Google Scholar
• Orchard TJ, Temprosa M, Goldberg R, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142(8):611–619.
   PubMed Web of Science ®Google Scholar
• Snehalatha C, Mary S, Joshi VV, et al. Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diab Vasc Dis Res. 2008;5(1):25–29.
   PubMed Web of Science ®Google Scholar
• Da Qing Diabetes Prevention Study Group. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019;7:452–461.
   PubMed Web of Science ®Google Scholar
• Diabetes Québec [Internet]. Coping with a diabetes diagnosis. [cited October 2019]. Available at https://www.diabete.qc.ca/en/living-with-diabetes/psychology/diagnosis/coping-with-a-diabetes-diagnosis
   Google Scholar
• Fujioka K, Brazg RL, Raz I, et al. Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies. Diabetes Obes Metab. 2005;7:28–39.
   PubMed Web of Science ®Google Scholar
• Fujioka K, Pans M, Joyal S. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation. Clin Ther. 2003;25(2):515–529.
   PubMed Web of Science ®Google Scholar
• Feher MD, Al-Mrayat M, Brake J, et al. Tolerability of prolonged-release metformin (Glucophage) in individuals intolerant to standard metformin: results from four UK centres. Diabetes Vasc Dis. 2007;7(5):225–228.
   Google Scholar
• Mahmood SE, Prakash D, Srivastava JP, et al. Prevalence of hypertension amongst adult patients attending out patient department of Urban Health Training Centre, Department of Community Medicine, Era's Lucknow Medical College and Hospital, Lucknow. J Clin Diagn Res. 2013;7:652–656.
   PubMedGoogle Scholar
• Zhao M, Lin H, Yuan Y, et al. Prevalence of pre-diabetes and its associated risk factors in rural areas of Ningbo, China. IJERPH. 2016;13(8) pii: 808.
   Google Scholar
• Wang R, Zhang P, Li Z, et al. The prevalence of pre-diabetes and diabetes and their associated factors in Northeast China: a cross-sectional study. Sci Rep. 2019;9(1):2513.
   PubMedGoogle Scholar